Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-0851

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma ; day:8 ; month:10 ; year:2021 ; pages:1-15
Cancer immunology immunotherapy ; (8.10.2021), 1-15

Creator: Cheng, Li
Creasy, Todd
Pilataxi, Fernanda
Greenlees, Lydia
Vence, Luis
Sridhar, Sriram
Streicher, Katie

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00262-021-03065-5

URN: urn:nbn:de:101:1-2021122507423986375167

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Cheng, Li
Creasy, Todd
Pilataxi, Fernanda
Greenlees, Lydia
Vence, Luis
Sridhar, Sriram
Streicher, Katie
SpringerLink (Online service)

Other Objects (12)

Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer

Non-small-cell lung cancer

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study

Arzneimittel Profil Durvalumab

Durvalumab (small cell lung cancer) : Addendum to Commission A20-87

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)

Hochschulschrift

Pharmacometric applications in non-small-cell lung cancer

Deep learning-based tumor microenvironment segmentation is predictive of tumor mutations and patient survival in non-small-cell lung cancer

Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer

Non-small-cell lung cancer

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study

Arzneimittel Profil Durvalumab

Durvalumab (small cell lung cancer) : Addendum to Commission A20-87

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)

Hochschulschrift

Pharmacometric applications in non-small-cell lung cancer

Deep learning-based tumor microenvironment segmentation is predictive of tumor mutations and patient survival in non-small-cell lung cancer

Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer

Non-small-cell lung cancer

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study

Arzneimittel Profil Durvalumab

Durvalumab (small cell lung cancer) : Addendum to Commission A20-87

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)

Hochschulschrift

Pharmacometric applications in non-small-cell lung cancer

Deep learning-based tumor microenvironment segmentation is predictive of tumor mutations and patient survival in non-small-cell lung cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer

Non-small-cell lung cancer

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study

Arzneimittel Profil Durvalumab

Durvalumab (small cell lung cancer) : Addendum to Commission A20-87

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)

Pharmacometric applications in non-small-cell lung cancer

Deep learning-based tumor microenvironment segmentation is predictive of tumor mutations and patient survival in non-small-cell lung cancer

Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer

Non-small-cell lung cancer

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study

Arzneimittel Profil Durvalumab

Durvalumab (small cell lung cancer) : Addendum to Commission A20-87

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)

Pharmacometric applications in non-small-cell lung cancer

Deep learning-based tumor microenvironment segmentation is predictive of tumor mutations and patient survival in non-small-cell lung cancer

Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer

Non-small-cell lung cancer

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study

Arzneimittel Profil Durvalumab

Durvalumab (small cell lung cancer) : Addendum to Commission A20-87

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)

Pharmacometric applications in non-small-cell lung cancer

Deep learning-based tumor microenvironment segmentation is predictive of tumor mutations and patient survival in non-small-cell lung cancer

Related objects

Reset password